Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents.
OBJECTIVE
We compared the healing and inflammatory responses of polymer-free bare-metal stents (BMS), polymer-free sirolimus-eluting stents (SES) and polymer-free sirolimus-eluting stents plus estradiol (SES+ED) to Cypher drug-eluting stents (CDES) in a rabbit model of overlapping stent placement.


BACKGROUND
Inflammatory responses to polymers and delayed healing remain important safety issues associated with CDES. Whether nonpolymeric stents that elute sirolimus or sirolimus and estradiol provoke less inflammation and heal better is unknown.


METHODS
Twenty-eight rabbits received 2 overlapping stents in each iliac artery: SES, SES+ED, BMS, or CDES, and vessels were harvested at 28 days for histology and scanning electron microscopy.


RESULTS
Although similar at nonoverlapping segments, neointimal thickness within the overlap site of CDES was significantly less than in SES, SES+ED, and BMS (0.07 +/- 0.04 mm vs. 0.16 +/- 0.03 mm, 0.14 +/- 0.03 mm, and 0.15 +/- 0.03 mm, p < 0.0001). Endothelialization was greater in SES, SES+ED, and BMS compared with CDES in nonoverlapping sections (80.0 +/- 5.0% vs. 95.3 +/- 5.0%, 97.5 +/- 2.5%, and 96.7 +/- 3.8%; p = 0.0028) and overlapping sections (85.8 +/- 2.9% vs. 90.8 +/- 6.3%, 89.2 +/- 6.3%, and 48.3 +/- 2.9%; p < 0.0001). The number of luminal eosinophils was also less in overlapping sections of SES, SES+ED, and BMS versus CDES but was similar in nonoverlapping sections.


CONCLUSIONS
Polymer-free stents coated with SES or SES+ED result in less robust neointimal suppression but markedly improved arterial healing compared with CDES in the rabbit model.
John
Michael C
MC
Department of Internal Medicine, Massachusetts General Hospital, Boston, USA.
Wessely
Rainer
R
Kastrati
Adnan
A
Schömig
Albert
A
Joner
Michael
M
Uchihashi
Mayu
M
Crimins
Johanna
J
Lajoie
Scott
S
Kolodgie
Frank D
FD
Gold
Herman K
HK
Virmani
Renu
R
Finn
Aloke V
AV
D000800:Angioplasty, Balloon / Q000009:adverse effects / Q000295:instrumentation*; D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016207:Cytokines / Q000378:metabolism; D054855:Drug-Eluting Stents; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D007083:Iliac Artery / Q000187:drug effects* / Q000293:injuries / Q000378:metabolism / Q000648:ultrastructure; D007249:Inflammation / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D008670:Metals; D008855:Microscopy, Electron, Scanning; D023421:Models, Animal; D009924:Organ Culture Techniques; D011108:Polymers; D011474:Prosthesis Design; D011817:Rabbits; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D014945:Wound Healing / Q000187:drug effects*
D002317:Cardiovascular Agents; D016207:Cytokines; D005343:Fibrinolytic Agents; D036341:Intercellular Signaling Peptides and Proteins; D008670:Metals; D011108:Polymers; D020123:Sirolimus